BRPI0921845A2 - formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata - Google Patents

formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata

Info

Publication number
BRPI0921845A2
BRPI0921845A2 BRPI0921845A BRPI0921845A BRPI0921845A2 BR PI0921845 A2 BRPI0921845 A2 BR PI0921845A2 BR PI0921845 A BRPI0921845 A BR PI0921845A BR PI0921845 A BRPI0921845 A BR PI0921845A BR PI0921845 A2 BRPI0921845 A2 BR PI0921845A2
Authority
BR
Brazil
Prior art keywords
treating
germinal
depleting
primate
disrupting
Prior art date
Application number
BRPI0921845A
Other languages
English (en)
Inventor
Shah Ambarish
Carlesso Gianluca
Sathish Hasige
Delaney Tracy
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of BRPI0921845A2 publication Critical patent/BRPI0921845A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata aqui descritas estão formulações líquidas de anticorpos e fragmentos biologicamente ativos dos mesmos que se ligam especificamente a um polipeptídeo icos humano, exibem atividade adcc in vivo elevada e sofrem autoassociação .reversível em solução.
BRPI0921845A 2008-11-12 2009-11-12 formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata BRPI0921845A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11379608P 2008-11-12 2008-11-12
US24936509P 2009-10-07 2009-10-07
PCT/US2009/064127 WO2010056804A1 (en) 2008-11-12 2009-11-12 Antibody formulation

Publications (1)

Publication Number Publication Date
BRPI0921845A2 true BRPI0921845A2 (pt) 2019-09-17

Family

ID=42170314

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921845A BRPI0921845A2 (pt) 2008-11-12 2009-11-12 formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata

Country Status (9)

Country Link
US (3) US20110293605A1 (pt)
EP (1) EP2358392B1 (pt)
JP (2) JP5933975B2 (pt)
CN (1) CN102438652B (pt)
AU (1) AU2009314099B2 (pt)
BR (1) BRPI0921845A2 (pt)
CA (1) CA2743469C (pt)
ES (1) ES2719496T3 (pt)
WO (1) WO2010056804A1 (pt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
US9658156B2 (en) * 2010-03-03 2017-05-23 Wyatt Technology Corporation Method of characterizing interactions and screening for effectors
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
CN103249432A (zh) * 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
PT2625199T (pt) 2010-10-08 2018-02-28 Novartis Ag Métodos de tratamento de psoríase usando antagonistas de il-17
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
US9376493B2 (en) * 2011-03-31 2016-06-28 INSERM (Institut National de la Sante et de la Recherche Mediacale) Antibodies directed against ICOS and uses thereof
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
AU2014264228A1 (en) * 2013-05-07 2015-11-12 Bio Blast Pharma Ltd. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
AU2014352891B2 (en) * 2013-11-20 2019-09-12 The Regents Of The University Of California Identification of a novel B cell cytokine
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
JP6665485B2 (ja) * 2015-10-29 2020-03-13 東ソー株式会社 抗体依存性細胞傷害活性に基づく抗体の分析方法
CA3006930A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017106129A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
ES2781474T3 (es) 2016-04-07 2020-09-02 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
PE20181884A1 (es) 2016-04-07 2018-12-07 Glaxosmithkline Ip Dev Ltd Amidas heterociclicas utiles como moduladores de proteinas
SG11201809560QA (en) 2016-05-05 2018-11-29 Glaxosmithkline Ip No 2 Ltd Enhancer of zeste homolog 2 inhibitors
CA3026880A1 (en) * 2016-06-08 2017-12-14 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells in igg4-related diseases
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018015879A1 (en) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
EP3497128A2 (en) 2016-08-09 2019-06-19 Kymab Limited Anti-icos antibodies
US10793632B2 (en) * 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
PL3570882T3 (pl) * 2017-01-19 2022-02-07 Bayer Pharma Aktiengesellschaft Nowa stabilna formulacja dla przeciwciał fxia
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
EP3635011A1 (en) 2017-06-09 2020-04-15 GlaxoSmithKline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
WO2018225034A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
CA3066048A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
WO2019053613A2 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
CN111417630B (zh) 2017-10-05 2023-06-06 葛兰素史克知识产权开发有限公司 干扰素基因刺激因子(sting)的调节剂
IL297354A (en) * 2017-11-30 2022-12-01 Bio Thera Solutions Ltd A liquid preparation of a humanized antibody for the treatment of 6-il-related disease
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CN112469441A (zh) 2018-05-31 2021-03-09 葛兰素史克知识产权开发有限公司 用icos结合蛋白和精氨酸甲基转移酶抑制剂的组合疗法
CN112469416A (zh) 2018-05-31 2021-03-09 葛兰素史克知识产权开发有限公司 用于治疗癌症的ii型蛋白质精氨酸甲基转移酶抑制剂和icos结合蛋白的组合
PH12021550096A1 (en) * 2018-07-20 2022-03-28 Momenta Pharmaceuticals Inc Compositions of fcrn antibodies and methods of use thereof
AU2019307959B2 (en) 2018-07-20 2025-09-25 Momenta Pharmaceuticals, Inc. FcRn antibody compositions
WO2020031087A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
CA3117746A1 (en) * 2018-10-22 2020-04-30 Glaxosmithkline Intellectual Property Development Limited Dosing
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021046293A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
BR112022004941A2 (pt) 2019-09-20 2022-06-28 Novartis Ag Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
EP4034562B1 (en) 2019-09-27 2025-10-29 GlaxoSmithKline Intellectual Property Development Limited Antigen binding proteins
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
CA3171557A1 (en) 2020-04-14 2021-10-21 Marc S. BALLAS Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
AU2021256925A1 (en) 2020-04-14 2022-11-03 Ares Trading S.A. Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
AU2021257570A1 (en) 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
CN115551553A (zh) * 2020-05-12 2022-12-30 Inserm(法国国家健康医学研究院) 治疗皮肤t细胞淋巴瘤和tfh起源淋巴瘤的新方法
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
JP2024505128A (ja) * 2020-12-30 2024-02-05 アイ－エムエービー バイオファーマ カンパニー リミテッド 抗ｃｄ７３抗体の製剤
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
CN116917273A (zh) 2021-03-02 2023-10-20 葛兰素史克知识产权发展有限公司 作为dnmt1抑制剂的经取代的吡啶
US20240166747A1 (en) 2021-03-31 2024-05-23 Glazosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US12580047B2 (en) 2022-01-18 2026-03-17 Dell Products L.P. Biological sequence compression using sequence alignment
US12530320B2 (en) 2022-01-18 2026-01-20 Dell Products L.P. File compression using sequence splits and sequence alignment
US12572509B2 (en) 2022-01-18 2026-03-10 Dell Products L.P. Structure based file compression using sequence alignment
US12353358B2 (en) 2022-01-18 2025-07-08 Dell Products L.P. Adding content to compressed files using sequence alignment
US12511260B2 (en) 2022-01-18 2025-12-30 Dell Products L.P. File compression using sequence alignment
US11977517B2 (en) 2022-04-12 2024-05-07 Dell Products L.P. Warm start file compression using sequence alignment
US12216621B2 (en) 2022-04-12 2025-02-04 Dell Products L.P. Hyperparameter optimization in file compression using sequence alignment
US12339811B2 (en) * 2022-04-12 2025-06-24 Dell Products L.P. Compressing multiple dimension files using sequence alignment
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US560181A (en) 1896-05-12 Elizabeth howard administratrix of said tom howard
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US5851526A (en) 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH0684377B2 (ja) 1986-04-17 1994-10-26 協和醗酵工業株式会社 新規化合物ｄｃ―８８ａ及びｄｃ―８９ａ１
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A7 (fi) 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5360716A (en) 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
CA2046909A1 (en) 1989-03-21 1990-09-22 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
DE69031919T3 (de) 1989-07-19 2005-01-27 Connetics Corp., Palo Alto T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5644034A (en) 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
DE4006269A1 (de) 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69130709T3 (de) 1990-10-05 2005-12-22 Celldex Therapeutics, Inc. Gezielte immunostimulierung mit bispezifischen stoffen
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
EP0571442A4 (en) 1991-01-14 1995-05-03 Univ New York PROTEIN TSG-14 INDUCED BY CYTOKINE, DNA ENCODING THE PROTEIN AND USES THEREOF.
DE69219913T2 (de) 1991-01-15 1997-09-11 Bayer Ag Ergänzung von Oberflächenrezeptoren
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE69214709T2 (de) 1991-04-26 1997-02-20 Surface Active Ltd Neue Antikörper und Verfahren zu ihrer Verwendung
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5334380A (en) 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4135070C1 (pt) 1991-10-24 1993-05-19 Institut Fuer Rundfunktechnik Gmbh, 8000 Muenchen, De
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
EP0627940B1 (en) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
ATE155043T1 (de) 1992-10-08 1997-07-15 Kennedy Inst Of Rheumatology Behandlung von autoimmun- und entzundungskrankheiten
AU682670B2 (en) 1993-02-05 1997-10-16 Becton Dickinson & Company Syringe needle isolation device
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69531148T2 (de) 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
JPH07309761A (ja) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
EP0766564A4 (en) 1994-06-24 1998-09-23 Immunex Corp SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5607400A (en) 1995-05-19 1997-03-04 Becton, Dickinson And Company Pre-fillable syringe and stopper assembly therefor
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
SE9504046D0 (sv) 1995-11-14 1995-11-14 Pharmacia Ab Method of determining affinity and kinetic properties
JPH09173450A (ja) 1995-12-26 1997-07-08 Nissho Corp プレフィルドシリンジ
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE247830T1 (de) 1996-05-23 2003-09-15 Inverness Medical Switzerland Verbesserungen in oder in bezug auf spezifische bindungsassays
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
JP3293122B2 (ja) 1996-12-13 2002-06-17 ニプロ株式会社 プレフィルドシリンジ
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5968741A (en) 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
SE9703425D0 (sv) 1997-09-23 1997-09-23 Pharmacia & Upjohn Ab Prefilled ampooules and manufacture thereof
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
DE19751219A1 (de) 1997-11-19 1999-05-27 Vetter & Co Apotheker Spritze, insbesondere vorgefüllte Spritze, oder Karpule
EP2253549B1 (en) 1998-03-13 2015-03-04 Becton Dickinson and Company Method for manufacturing, filling and packaging medical containers
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6114517A (en) 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
EP1094110A1 (en) 1999-10-21 2001-04-25 Leadd B.V. Apoptosis inducing proteinaceous substance
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
JP3591636B2 (ja) 2000-04-03 2004-11-24 ニプロ株式会社 プレフィルドシリンジ
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
EP2264072A1 (en) 2000-04-13 2010-12-22 The Rockefeller University Enhancement of antibody-mediated cytotoxicity.
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
AU2001276842B2 (en) 2000-06-28 2007-04-26 Glycofi, Inc. Methods for producing modified glycoproteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2433877C (en) 2001-01-17 2014-11-18 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002322478A1 (en) 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP4141156B2 (ja) 2002-03-15 2008-08-27 日本ベクトン・ディッキンソン株式会社 プランジャ後退制限機構付きプレフィルドシリンジ
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
ATE552873T1 (de) 2002-07-02 2012-04-15 Terumo Corp Spritze und vorgefüllte spritze
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
DE10254321A1 (de) 2002-11-21 2004-06-17 Arzneimittel Gmbh Apotheker Vetter & Co. Ravensburg Vorgefüllte Spritze
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2004229750A (ja) 2003-01-28 2004-08-19 Nipro Corp プレフィルドシリンジ及びそのバレルの製造方法
US8932603B2 (en) 2003-02-25 2015-01-13 Vaccibody As Modified antibody
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
US20050075611A1 (en) 2003-10-01 2005-04-07 Hetzler Kevin G. Low extractable, thermoplastic syringe and tip cap
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
EP2801583B1 (en) 2004-07-10 2018-04-25 Fox Chase Cancer Center Genetically modified human natural killer cell lines
ES2426817T3 (es) 2004-08-04 2013-10-25 Mentrik Biotech, Llc Regiones Fc variantes
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7988675B2 (en) 2005-12-08 2011-08-02 West Pharmaceutical Services Of Delaware, Inc. Automatic injection and retraction devices for use with pre-filled syringe cartridges
JP4682850B2 (ja) 2006-01-12 2011-05-11 ニプロ株式会社 プレフィルドシリンジ
US8497246B2 (en) * 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
CA2663388C (en) * 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
AU2007294575B2 (en) * 2006-09-08 2013-06-27 Viela Bio, Inc. Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008116103A2 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
AU2008232903B9 (en) * 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
JP5575636B2 (ja) * 2007-05-07 2014-08-20 メディミューン，エルエルシー 抗ｉｃｏｓ抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Also Published As

Publication number Publication date
US20170174766A1 (en) 2017-06-22
CA2743469C (en) 2019-01-15
CN102438652B (zh) 2014-08-13
EP2358392A4 (en) 2012-08-29
JP2015163618A (ja) 2015-09-10
JP2012508755A (ja) 2012-04-12
CN102438652A (zh) 2012-05-02
EP2358392A1 (en) 2011-08-24
AU2009314099A1 (en) 2010-05-20
US20110293605A1 (en) 2011-12-01
US20200216541A1 (en) 2020-07-09
ES2719496T3 (es) 2019-07-10
CA2743469A1 (en) 2010-05-20
JP5933975B2 (ja) 2016-06-15
EP2358392B1 (en) 2019-01-09
AU2009314099B2 (en) 2016-03-24
WO2010056804A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
BRPI0921845A2 (pt) formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
Kim et al. Autologous platelet-rich plasma versus dextrose prolotherapy for the treatment of chronic recalcitrant plantar fasciitis
US20220040225A1 (en) Method of administration and treatment
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
JP6568052B2 (ja) 心不全を治療するためのニューレグリンの徐放
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
NI201100194A (es) Derivados de tieno [2, 3 - b] piridina como inhibidores de la replicación viral
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
KR20190035957A (ko) 항종양제의 투여 방법
RU2015103107A (ru) Комбинированная композиция
CY1113575T1 (el) Χρηση συνθεσεων οπιοειδων σε συσκευες χορηγησης δραστικης ουσιας χωρις βελονα
ECSP13012399A (es) Un nuevo conjugado de granulocito colonia-estimulante factor (g-csf) con polietileno
US20140328826A1 (en) Product and method for treating keloid scars, hypertrophic scars and burn scars with contracture
EP2446884B1 (en) Composition for inhibiting inflammation comprising hyaluronic acid and a hmg-coa reductase inhibitor
Thiry et al. Evaluation of flunixin meglumine pour-on administration on prostaglandin E2 concentration in inflammatory exudate after induction of inflammation in cattle
HRP20161147T1 (hr) Farmaceutski sastav i postupak njegove proizvodnje
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
US9687518B2 (en) Medicament for treating muscle and skeletal diseases
Özgen et al. Short-and long-term results of clinical effectiveness of sodium hyaluronate injection in supraspinatus tendinitis
AR077427A1 (es) Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st
EA201170319A1 (ru) Приложение напряжения сдвига для лечения заболеваний
Perrien et al. Percutaneous injection of augment injectable bone graft (rhPDGF-BB and β-tricalcium phosphate [β-TCP]/bovine type I collagen matrix) increases vertebral bone mineral density in geriatric female baboons
RU2537031C2 (ru) Способ лечения цистита
US20210023140A1 (en) Platelet formulations and medical uses thereof
Abbasi et al. Transdermal delivery of metformin using microneedle and iontophoresis for combating obesity

Legal Events

Date Code Title Description
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2542 DE 24-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]